PARIS, FRANCE, 23 July 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the following changes to its Executive Committee:
Solid low-cost production profile from year one via a phased mine plan:Phase 1: Low Initial capital cost of $155 million, builds average annual gold...
Solid low-cost production profile from year one via a phased mine plan:Phase 1: Low Initial capital cost of $155 million, builds average annual gold...
A first-of-its-kind solution for women’s arousal - the same active ingredient as in Viagra® for men - in a proprietary topical formulation demonstrated to work where women need it most
DELRAY BEACH, Fla., July 21, 2025 /PRNewswire/ -- The global Healthcare Consulting Services Market, valued at US$29.11 billion in 2024, stood at US$32.17 billion in...
NetworkNewsWire Editorial Coverage
NEW YORK, July 21, 2025 /PRNewswire/ -- Gold's remarkable surge beyond $3,300 per ounce (all figures are in U.S. dollars unless otherwise noted)...
NetworkNewsWire Editorial Coverage
NEW YORK, July 21, 2025 /PRNewswire/ -- Gold's remarkable surge beyond $3,300 per ounce (all figures are in U.S. dollars unless otherwise noted)...
NetworkNewsWire Editorial Coverage
NEW YORK, July 21, 2025 /CNW/ -- Gold's remarkable surge beyond $3,300 per ounce (all figures are in U.S. dollars unless otherwise noted)...
EXTON, Pa., July 21, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced...
NASHVILLE, Tenn., July 16, 2025 /PRNewswire/ -- RxPreferred, a leading transparent pharmacy benefit administrator, is proud to announce the launch of My-RxP, an innovative medication...
HONG KONG, July 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been successfully...
BASSETT, Va., July 09, 2025 (GLOBE NEWSWIRE) -- Bassett Furniture Industries, Inc. (Nasdaq: BSET) reported today its results of operations for its second quarter ended May 31, 2025.
Basel, July 8, 2025 – Novartis today announced Coartem® (artemether-lumefantrine) Baby has been approved by Swissmedic as the first malaria medicine for newborns and young infants. The new treatment, also known as Riamet® Baby in some countries, was developed in collaboration with Medicines for Malaria Venture (MMV) to treat the potentially deadly mosquito-borne disease.